ReviewViruses2018
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy.
Review in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 357 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
357 citing papers in PubMed.
- Intra-species competition combats vancomycin-resistant enterococci.Gut microbes · 2026Article
- Experimental evolution of phage K enhances antibacterial activity against USA300 MRSA in lung infection models.Emerging microbes & infections · 2026Article
- Phenotypic heterogeneity and genetic mechanisms of phage resistance in hypervirulent carbapenem-resistantVirulence · 2026Article
- AApplied and environmental microbiology · 2026Article
- Characterization and genomic analysis of a jumbo Aeromonas hydrophila phage BMBAH1, representing a candidate novel viral genus.Virus research · 2026Article
- Rapid phage susceptibility determination using a semi-automated bioluminescent ATP assay.Microbiology spectrum · 2026Article
- Vancomycin and phage COP-80B combination therapy for Staphylococcus epidermidis periprosthetic joint infections: a preclinical mouse study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Bacteriophages Control Epiphytic Pseudomonas syringae Populations in Highbush Blueberry Leaves.Microbial biotechnology · 2026Article
- Article
- Bacteriophage Therapy for Breast Implants: A Translational Perspective and Future Directions.Plastic and reconstructive surgery. Global open · 2026Article
- Bacteriophage-induced outer membrane protein remodelling drives the phenotypic switching and antibiotic re-sensitization in Klebsiella pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Bacteriophage cocktails and bacterial coevolution: a systematic review of resistance prevention strategies against multidrug-resistant pathogens in sewage water.Iranian journal of microbiology · 2026Article
- Dose-and regimen-dependent therapeutic efficacy of the lytic Klebsiella phage TRK61 in a Galleria mellonella infection model.Archives of virology · 2026Article
- Giving Antibiotics a Second Chance: Evolutionary Trade-Offs and Phage-Driven Restoration of Antibiotic Susceptibility.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges.Archives of microbiology · 2026Review
- Antibacterial potential of five phages in controlling Enterococcus faecalis and Enterococcus faecium.Virology journal · 2026Article
- Phenotypic heterogeneity shapes phage resistance and cocktail efficacy inMicrobiology spectrum · 2026Article
- Characterisation and In Planta Activity of Bacteriophages That Infect the Key Bacterial Species Associated With Acute Oak Decline.Microbial biotechnology · 2026Article
- A review on antibiotic and non-antibiotic decolonization strategies of multidrug-resistant bacteria in the gastrointestinal tract.Infection · 2026Review
- Robust detection in faeces andVeterinary and animal science · 2026Article
297 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophage (phage) therapy, i.e., the use of viruses that infect bacteria as antimicrobial agents, is a promising alternative to conventional antibiotics. Indeed, resistance to antibiotics has become a major public health problem after decades of extensive usage. However, one of the main questions regarding phage therapy is the possible rapid emergence of phage-resistant bacterial variants, which could impede favourable treatment outcomes. Experimental data has shown that phage-resistant variants occurred in up to 80% of studies targeting the intestinal milieu and 50% of studies using sepsis models. Phage-resistant variants have also been observed in human studies, as described in three out of four clinical trials that recorded the emergence of phage resistance. On the other hand, recent animal studies suggest that bacterial mutations that confer phage-resistance may result in fitness costs in the resistant bacterium, which, in turn, could benefit the host. Thus, phage resistance should not be underestimated and efforts should be made to develop methodologies for monitoring and preventing it. Moreover, understanding and taking advantage of the resistance-induced fitness costs in bacterial pathogens is a potentially promising avenue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.